Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission

International Heart Journal

Volumn 50, Issue 1, 2009, Pages 33-45

  Akkus, Mehmet Necdet ^a   Polat, Gurbuz ^a   Yurtdas, Mustafa ^a   Akcay, Burak ^a   Ercetin, Neslihan ^a   Cicek, Dilek ^a   Doven, Oben ^a   Sucu, Nehir ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acute coronary syndromes; Fibrinolysis processes; Inflammatory processes; Left ventricular systolic dysfunction; Mortality

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; HYPERTENSIVE FACTOR; INOTROPIC AGENT; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIROFIBAN;

ACUTE HEART INFARCTION; AGED; AORTA BALLOON; ARTICLE; CARDIOGENIC SHOCK; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEPHELOMETRY AND TURBIDIMETRY; ODDS RATIO; PATIENT ADMISSION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; SURVIVAL RATE; TURKEY;

EID: 61749086582     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.33     Document Type: Article

References (48)

1. Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999: 340: 115-26. (Review)
2. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes. Clin Cardiol 2007; 30: 26-31.
3. Potsch AA, Siqueira Filho AG, Tura BR, et al. C-reactive protein diagnostic and prognostic value in patients presenting at the emergency room with chest pain. Arq Bras Cardiol 2006; 87: 275-80. (English, Portuguese)
4. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000; 140: 324-8.
5. Zairis MN, Manousakis SI, Stefanidis AS, et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002; 144: 782-9.
6. Brunetti ND, Pellegrino PL, Correale M, De Gennaro L, Cuculo A, Di Biase M. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. J Thromb Thrombolysis 2008; 26: 196-202.
7. Hochman IS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107: 2998-3002. (Review)
8. Lim SY, Jeong MH, Bae EH, et al. Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention. Circ J 2005; 69: 154-8.
9. Bae EH, Lim SY, Jeong MH, et al. Long-term predictive factors of major adverse cardiac events in patients with acute myocardial infarction complicated by cardiogenic shock. Korean J Intern Med 2005; 20: 8-14.
10. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993; 70: 530-6.
11. Ganti AK, Potti A, Yegnanarayan R. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction. Pathophysiol Haemost Thromb 2002; 32: 80-4.
12. Sinkovic A. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am Heart J 1998; 136: 406-11.
13. Ioannidou-Papayannaki E, Lefkos N, Boudanas G, et al. Alterations in the fibrinolylic system components during acute myocardial infarction. Acta Cardiol 2000; 55: 247-53.
14. Sinkovic A, Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb Res 2004; 114: 251-7.
15. El Menyar AA, Altamimi OM, Gomaa MM, Fawzy Z, Rahman MO, Bener A. The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction. J Thromb Thrombolysis 2006; 21: 235-40.
16. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108: 391-4.
17. Gomes WJ, Buffolo E. Coronary stenting and inflammation: implications, for further surgical and medical treatment. Ann Thorac Surg 2006; 81: 1918-25. (Review)
18. Christ G, Nikfardjam M, Huber-Beckmann R, et al. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication. J Thromb Haemost 2005; 3: 233-9.
19. Biglioli P, Cannata A, Alamanni F, et al. Biological effects of off-pump versus on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress. Eur J Cardiothorac Surg 2003: 24: 260-9. (Review)
20. Andreotti F. Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991:8: 336-51. (Review)
21. Huber K, Rosc D, Resh I, et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 1988; 60: 372-6.
22. Fujino T, Katou J, Fujita M, et al. Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction. Atherosclerosis 2001; 155: 171-8.
23. Alpert JS, Thygesen K, Antman E. Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000: 36: 959-69. (Guideline)
24. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Eng J Med 1999; 341: 625-34.
25. Plomgaard P, Keller P, Keller C, Pedersen BK. TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. J Appl Physiol. 2005; 98: 2019-23.
26. Frangogiannis NG, Smith CW. Eniman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 3147. (Review)
27. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings, Int J Cardiol 2006: 109: 248-56.
28. Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphqlogy in patients with acute myocardial infarction. Circulation 2003; 108: 282-5.
29. Nijmeijer R, Lagrand WK, Visser CA, Meijer CJ, Niessen HW, Hack CE. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Int Immunopharmacol 2001; 1: 403-14. (Review)
30. Anzai T, Yoshikawa T, Shiraki H, et al. C-reactive protein as a predictor of infarct expansion, and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997: 96: 778-84.
31. Ali AS, Rybicki BA, Alam M, et al. Clinical predictors of heart failure in patients with first myocardial infarction. Am Heart J 1999; 138: 1133-9.
32. Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med 1993; 94: 265-73.
33. Riouful G, Zeller M, Dentan G, et al. Predictors and prognosis for complex coronary lesions in patients with acute myocardial infarction: data from RICO survey. Am Heart J 2007; 154: 330-5.
34. Ohlmann P, Jaquemin L, Morel O, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J 2006; 152: 1161-7.
35. Lindholm MG, Boesgaard S, Torp-Pedersen C, Køber L, TRACE registry study group. Diabetes mellitus and cardiogenic shock in acute myocardial infarction. Eur J Heart Fail 2005; 7: 834-9.
36. O'Connor CM, Hathaway WR, Bates ER, et al. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J 1997; 133: 663-73,
37. Moreno R, García E, Elízaga J, et al. Results of primary angioplasty in patients with multivessel disease. Rev Esp Cardiol 1998; 51: 547-55. (Spanish)
38. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98: 149-56.
39. Kotlyar E, Vita JA, Winter MR, et al. The relationship between aldosterone, oxidative stress, and inflammation in chronic stable human heart failure. J Card Fail 2006: 12: 122-7.
40. Kimura K, Kosuge M, Ishikawa T, et al. Relationship between myocardial damage and C-reactive protein levels immediately after onset of acute myocardial infarction. Jpn Circ J 2001; 65: 67-70.
41. Thögersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
42. Folsom AR. Aleksic N. Park E. Salomaa V. Juneja H. Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities.(ARIC) Study. Arterioscler Thromb Vasc Bio1 2001; 21: 611-7.
43. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Eng J Med 1989; 320: 1165-72.
44. de Boer JP, Abbink JJ, Brouwer MC, et al. PAI- 1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines - evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65: 181-5.
45. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 2006; 97: 13F-25. (Review)
46. Edep ME, Brown DL. Effect of early revascularization on mortality from cardiogenic shock complicating acute myocardial infarction in California. Am J Cardiol 2000; 85: 1185-8.
47. Askari AT, Brennan ML, Zhou X, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003; 197: 615-24.
48. Takeshita K, Hayashi M, Iino S, et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 2004: 164: 449-56.